Clinical Use of the BIOFIRE® GLOBAL FEVER (GF) PANEL

6

TARGETS

50 min

BIOFIRE DEFENSE

Who Should Get Tested

According to guidelines for return travelers to the United States, individuals with signs, symptoms, and/or travel to areas of known or suspected outbreaks should be tested.[2]

- Adventure Tourists
- Business Travelers
- Aid Workers
- Long-Term Travelers
- Military Personnel
- Vacationers



The test should be performed on individuals returning to the US, who display one or more of the following criteria [1,2]:

- Community acquired fever for ≥3 days
- Traveler's fever, untreated or following treatment failure
- Fever with warning signs- bug bites
- Persistent fever

Aid Antimicrobial Stewardship

ANTIMICROBIAL STEWARDSHIP

Improved antibiotic use

Limit the use of unnecessary antimicrobials. Don't rely on front-line antibiotics, instead target the symptoms with the correct treatment by obtaining results in 50 minutes with the BioFire Global Fever Panel.

BioFire® FilmArray® PCR Testing Provides Faster Results

Reduce Time to Results

The combination of sensitivity and specificity, low contamination risk, and speed has made PCR technology an appealing alternative to culture- or immunoassay-based testing methods for aid in diagnosing many infectious diseases.[a]

BIOFIRE DEFENSE

BioFire Defense has been providing world-class products to the molecular diagnostics and biosurveillance industries for nearly 35 years.

After bioMérieux's acquisition of BioFire in 2014, BioFire Defense served as a separate entity with a mission to support the unique needs of the US Government.

Through our work with the US Government we developed the BioFire Global Fever Panel to help clinicians make faster, more accurate diagnoses of common tropical diseases.

BIOMÉRIEUX

bioMérieux and BioFire Defense are committed to make the world a safer place as a global leader in microbiology and infectious disease diagnostics.

BIOFIRE®

GLOBAL FEVER (GF) PANEL

1 Test, 6 Targets, in 50 Minutes

Bacterial
Leptospira spp.

Viral
Chikungunya virus
Dengue virus
(serotypes 1, 2, 3 and 4)

Protozoan
Plasmodium spp.
Plasmodium falciparum
Plasmodium vivax/ovale

US FDA cleared
IVD For In Vitro Diagnostic Use

Panel Details

For detection and identification of selected targets.

Kit	**BioFire Global Fever Panel**
Part No.	DFA2-ASY-0004
Sample Types	EDTA Whole Blood
Sample Volume	0.2 mL (200 µL)
Tests per Kit	6 Pack Kit
CLIA Complexity	Moderate

All kit components stored at room temperature (18 - 30ºC)

External Control Kit Details

For quality control and test performance monitoring.

Kit	**BIOFIRE SHIELD Control Kit for the BioFire Global Fever Panel**
Part No.	DFA2-ASY-0006
Tests per Kit	6 Positive External Control Injection Vials 6 Negative External Control Injection Vials

Clinical Performance Summary[3]

Analyte	Sensitivity/ PPA	Specificity/ NPA
Leptospira spp.	93.8%	99.8%
Chikungunya virus	100%	99.9%
Dengue virus (serotypes 1, 2, 3, and 4)	94%	100%
Plasmodium spp.	98.3%	99.2%
Plasmodium falciparum	92.7%	99.8%
Plasmodium vivax/ovale	92.7%	100%

Data established during a prospective clinical study.

Guidelines

1. CDC, (2018, Oct. 19). *Assessing Fever in a Returning Traveler with No Risk of Viral Hemorrhagic Fever.* https://www.cdc.gov/vhf/abroad/assessing-fever-returning-traveler-no-risk-viral-hemorrhagic-fever.html
2. CDC, (2023, May 1). *CDC Yellow Book: Health Information for International Travel,* https://wwwnc.cdc.gov/travel/page/yellowbook-home
3. BioFire Defense, (2022, Dec). *BioFire Global Fever Panel Instructions for Use,* https://www.biofiredefense.com/globalfeverpanel/

References

a. ASM Journals, (2006, Jan. 1). *Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing.* https://doi.org/10.1128/cmr.19.1.165-256.2006

Contact Us

BioFire Defense
79 West 4500 South, Suite 14
Salt Lake City, Utah 84107, USA
+1-801-262-3592
www.BioFireDefense.com

DFA2-PRT-0222-01